STOCK TITAN
  1. Home
  2. News
  3. TVTX

Travere Therapeutics, Inc. - TVTX STOCK NEWS

Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney, liver, and metabolic diseases. The company's key focus is the development of its investigational product candidate, sparsentan. This novel therapy is in late-stage development for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can lead to end-stage kidney disease.

Travere Therapeutics has made significant strides in its mission, marked by several recent achievements. The company reported positive topline data from the pivotal phase-III PROTECT study of sparsentan in IgAN, showing a substantial reduction in proteinuria and potential long-term benefits in preserving kidney function. This led to the conditional marketing authorization of sparsentan under the brand name FILSPARI® in Europe and anticipated full approval in the U.S.

Additionally, Travere Therapeutics is advancing other innovative therapies. The company is exploring the potential of pegtibatinase as the first disease-modifying treatment for classical homocystinuria (HCU), with topline data expected in 2026.

Travere's strategic partnerships, such as with CSL Vifor, amplify its reach and impact. CSL Vifor has exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand. Together, these companies are dedicated to bringing promising treatments to patients worldwide.

The company's financial condition remains robust, supported by a strong pipeline and successful trials. Travere's commitment to the rare disease community is evidenced by its relentless pursuit of better treatment options and its collaborative efforts with patients, families, and caregivers.

News

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) to present nine abstracts at upcoming conferences, showcasing FILSPARI's potential as a foundational treatment for IgAN. The data include subgroup analyses, preliminary findings, and insights on disease management, highlighting the Company's commitment to innovation in rare kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) granted 51,600 inducement equity grants to four new employees on March 10, 2024. The grants include 25,000 stock options and 26,600 restricted stock units outside the 2018 Equity Incentive Plan. The stock options have an exercise price of $7.99 per share, a 10-year term, and vest over four years. The RSUs also vest over four years, with 25% of shares vesting on each anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
none
-
News

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Rhea-AI Summary
Travere Therapeutics, Inc. submits sNDA to FDA for full approval of FILSPARI in IgA nephropathy based on positive 2-year Phase 3 PROTECT Study results, showing significant reduction in proteinuria and kidney function preservation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
News

Travere Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) will participate in upcoming investor conferences in March 2024. The company will be present at Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays 26th Annual Global Healthcare Conference. Live webcasts of the presentations will be available on Travere's investor page, with replays accessible for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
conferences
-
News

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

Rhea-AI Summary
The CHMP recommends conditional marketing authorization for sparsentan in Europe for the treatment of IgA nephropathy, a rare kidney disorder. If approved, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for IgAN patients. The decision is expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
News

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Travere Therapeutics reports strong financial results for Q4 2023 with 459 new patient start forms for FILSPARI, nearing sNDA submission for full approval in the US, CHMP opinion expected in Europe, and Phase 3 HARMONY Study progress. Net product sales reached $39.9 million for Q4 and $127.5 million for FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
earnings
News

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) will report its Q4 and full year 2023 financial results on February 15, 2024. The company will host a conference call and webcast to discuss the financial results and provide a general business update. The webcast and dial-in information can be accessed on the Investor page of Travere’s website. An archived version of the call will be available for 30 days on the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences earnings
-
News

Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

Rhea-AI Summary
Travere Therapeutics, Inc. (TVTX) will present at the Guggenheim 6th Annual Biotechnology Conference on February 8, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast and a replay will be available for 30 days. Investors can watch the webcast on the Investor page of Travere’s website at ir.travere.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
-
News

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Rhea-AI Summary
Travere Therapeutics, Inc. has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to patients in Japan and other countries in Asia. Renalys will hold regional rights to sparsentan for Japan, South Korea, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Travere will receive an upfront payment and be eligible to receive up to $120 million in regulatory, development, and sales-based milestone payments. Results from the urine protein/creatinine ratio (UP/C) endpoint in the study are expected in the second half of 2025 to support a submission for approval to PMDA. Travere has obtained a minority equity stake in Renalys and will be eligible to receive tiered royalties on net sales of sparsentan in Japan, South Korea, Taiwan, and the specified Southeast Asian nations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
none
News

Travere Therapeutics Provides Corporate Update and 2024 Outlook

Rhea-AI Summary
Travere Therapeutics, Inc. (NASDAQ: TVTX) announced preliminary net product sales of $15 million for FILSPARI in the fourth quarter of 2023, with total net product sales of $40 million. The company also expects to submit an sNDA to the FDA for FILSPARI in Q1 2024 and anticipates a CHMP opinion on potential approval of sparsentan in Europe. Additionally, a pivotal Phase 3 study of pegtibatinase in classical homocystinuria (HCU) is underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.66%
Tags
none

FAQ

What is the current stock price of Travere Therapeutics (TVTX)?

The current stock price of Travere Therapeutics (TVTX) is $17.18 as of December 20, 2024.

What is the market cap of Travere Therapeutics (TVTX)?

The market cap of Travere Therapeutics (TVTX) is approximately 1.5B.

What is the primary focus of Travere Therapeutics?

Travere Therapeutics focuses on developing therapies for rare kidney, liver, and metabolic diseases.

What is sparsentan?

Sparsentan is an investigational product candidate being developed by Travere Therapeutics for treating FSGS and IgAN.

What recent achievements has Travere Therapeutics made?

Travere Therapeutics has reported positive topline data from the phase-III PROTECT study of sparsentan in IgAN and received conditional marketing authorization for sparsentan in Europe.

What are the indications for FILSPARI®?

FILSPARI® is indicated for reducing proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.

Who are Travere Therapeutics' strategic partners?

CSL Vifor is a key strategic partner, holding exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand.

What is the potential significance of pegtibatinase?

Pegtibatinase has the potential to become the first disease-modifying treatment for classical homocystinuria, with topline data expected in 2026.

What are the key safety considerations for FILSPARI® therapy?

Safety considerations include monitoring for hepatotoxicity and embryo-fetal toxicity; the therapy is available only through a restricted program called the FILSPARI REMS.

What is the financial condition of Travere Therapeutics?

Travere Therapeutics maintains a robust financial condition supported by a strong pipeline and successful clinical trials.

How does Travere Therapeutics develop its therapies?

Travere collaborates closely with the rare disease community to understand their needs and develops life-changing therapies based on these insights.

Where can more information about Travere Therapeutics be found?

More information can be found on their official website, travere.com.

Stock TVTX logo
Travere Therapeutics, Inc.

Nasdaq:TVTX

TVTX Rankings

#2195 Ranked by Market Cap
N/A Ranked by Dividends

TVTX Stock Data

1.51B
84.68M
0.65%
99.01%
8.01%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO